S-Space College of Medicine/School of Medicine (의과대학/대학원) Internal Medicine (내과학전공) Journal Papers (저널논문_내과학전공)
Long-term trastuzumab (Herceptin (R)) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer
- Mueller, Volkmar; Clemens, Michael; Jassem, Jacek; Al-Sakaff, Nedal; Auclair, Petra; Nuesch, Eveline; Holloway, Debbie; Shing, Mona; Bang, Yung-Jue
- Issue Date
- BioMed Central
- BMC Cancer, Vol.18, p. 295
- Background: Trastuzumab (Herceptin (R) [H]) is the standard of care for HER2-positive locally advanced/metastatic breast cancer and gastric/gastroesophageal junction (GEJ) cancer. However, there is a paucity of data available on long-term H treatment of patients. The Rollover Protocol (ROP) Study was conducted to report safety data for patients with HER2-positive locally advanced/metastatic breast and gastric/GEJ cancer who have received long-term H therapy (>= 5 years and >= 3 years for breast and gastric/GEJ cancer, respectively). Methods: The ROP Study was a single-arm, multicenter, international continuation trial of H in patients who had previously completed a global Roche-sponsored trial with H therapy, had stable disease, and were receiving H at the end of the lead-in trial. Patients with chronic heart failure during the lead-in trial could be included following a risk-benefit analysis. The primary objectives were to provide H therapy to patients with HER2-overexpressing locally advanced/metastatic breast or gastric/GEJ cancer at the end of the lead-in study, and to follow the long-term outcomes and long-term overall safety in these patients. Results: Twenty-five of 69 patients enrolled in the ROP Study received long-term H therapy (19 breast cancer and 6 gastric/GEJ cancer). The median duration of H treatment for patients with breast cancer was 8 years 7 months, and 5 years 2 months for patients with gastric/GEJ cancer. The cardiac status of the patients remained stable over time, with no serious cardiac adverse events or marked changes in left ventricular ejection fraction (LVEF). The median overall worst LVEF measurement was 57.0%, and no patients experienced an LVEF of < 45% (range 47-63%). There were no serious adverse events related to study treatment. Conclusions: These results suggest that H has an acceptable safety profile and was well tolerated in patients who received long-term H therapy (>= 5 years and >= 3 years for breast and gastric/GEJ cancer, respectively). Further investigation and reporting of long-term H therapy would be valuable.